Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.48 |
| ▸ | BACE1 | P56817 | 4/20 | 0.48 |
| ▸ | BCHE | P06276 | 3/20 | 0.48 |
| ▸ | DRD4 | P21917 | 8/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14203079 | 1.00 | ACHE (0.48) | ACHEBACE1BCHEDRD4SIGMAR1 | |
| SCHEMBL5038396 | 1.00 | ACHE (0.48) | ACHEBACE1BCHEDRD4SIGMAR1 | |
| SCHEMBL14203086 | 0.92 | DRD4 (0.46) | ACHEBACE1BCHEDRD4SIGMAR1 | |
| SCHEMBL14580286 | 0.92 | DRD4 (0.46) | ACHEBACE1BCHEDRD4SIGMAR1 | |
| SCHEMBL5042288 | 0.92 | DRD4 (0.46) | ACHEBACE1BCHEDRD4SIGMAR1 | |
| SCHEMBL5437818 | 0.90 | SLC6A2 (0.45) | DRD4SIGMAR1SLC6A2DRD2DRD3 | |
| SCHEMBL14203040 | 0.90 | SLC6A2 (0.45) | DRD4SIGMAR1SLC6A2DRD2DRD3 | |
| SCHEMBL8284121 | 0.90 | SLC6A2 (0.45) | DRD4SIGMAR1SLC6A2DRD2DRD3 | |
| SCHEMBL5671331 | 0.88 | DRD4 (0.50) | DRD4SIGMAR1SLC6A2 | |
| SCHEMBL14228798 | 0.87 | SLC6A2 (0.46) | ACHEBACE1BCHEDRD4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | ELILILLY AND COMPANY A CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | ELILILLY AND COMPANY A CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | ELI LILY AND COMPANY (US) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | SLC6A2, SLC6A4, SLC6A3 | ACHE 746/4885BACE1 1350/4885BCHE 776/4885 |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | SLC6A2, SLC6A4, HTR5A | ACHE 1354/4885BACE1 3879/4885BCHE 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.